Cost-effectiveness of a novel, non-active implantable device as a treatment for refractory gastro-esophageal reflux disease.

Introduction of RefluxStop was estimated to extend life expectancy and improve quality of life of GERD patients when compared with MM, LNF and MSA. The results of the cost-effectiveness analysis demonstrated that RefluxStop is highly likely to be a cost-effective treatment option within NHS England.